IL6 and neoplasm: In clinical practice, physicians always seek a balance between protecting their own immunity and ensuring a good tumor response, prolonged use of immunosuppressive agents or use at ICI initiation may impede antitumor immune response, but Inhibitors of IL-6 can synergize with ICIs on tumor response and also prevent severe immune-related adverse events (irAEs) (30).